Fatostatin hydrobromide
Based on 56 publication(s) in Google Scholar
Fatostatin hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.52%
- CAS No.: 298197-04-3
- Formule: C18H19BrN2S
- Masse moléculaire:375.33
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Lipid Metabolism Compound Library
HY-L091
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Fatostatin hydrobromide
More- Nature. 2026 Apr;652(8108):209-219. [Abstract]
- Cancer Cell. 2024 Sep 26:S1535-6108(24)00350-7. [Abstract]
- Cell Metab. 2021 Aug 3;33(8):1655-1670.e8. [Abstract]
- Cell Mol Immunol. 2025 Oct 29. [Abstract]
- Autophagy. 2021 Jul;17(7):1592-1613. [Abstract]
- Nat Commun. 2026 Jan 20;17(1):614. [Abstract]
- Nat Commun. 2025 Feb 25;16(1):1774. [Abstract]
- Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]
- J Clin Invest. 2025 Jul 8:e193134. [Abstract]
- J Exp Clin Cancer Res. 2019 May 29;38(1):228. [Abstract]
- Adv Sci (Weinh). 2025 Apr 24:e2407671. [Abstract]
- Cell Death Differ. 2021 Jun;28(6):2001-2018. [Abstract]
- Cell Death Dis. 2026 Jan 7;17(1):5. [Abstract]
- Cell Death Dis. 2025 May 16;16(1):391. [Abstract]
- Cell Mol Biol Lett. 2024 Aug 21;29(1):112. [Abstract]
- Cell Death Dis. 2024 Jun 12;15(6):411. [Abstract]
- Cell Death Dis. 2021 May 26;12(6):544. [Abstract]
- Cancer Lett. 2024 Jun 18:217068. [Abstract]
- Cell Death Discov. 2022 Oct 28;8(1):431. [Abstract]
- NPJ Precis Oncol. 2024 Mar 1;8(1):58. [Abstract]
- Mol Med. 2024 Feb 21;30(1):28. [Abstract]
- Free Radic Biol Med. 2025 Aug 19:240:170-182. [Abstract]
- Cancer Immunol Res. 2025 Dec 9. [Abstract]
- Cell Rep. 2025 Feb 19;44(3):115339. [Abstract]
- Cell Rep. 2022 Nov 29;41(9):111738. [Abstract]
- Emerg Microbes Infect. 2025 Dec;14(1):2470371. [Abstract]
- J Ethnopharmacol. 2026 Feb 28:357:120890. [Abstract]
- JCI Insight. 2024 Jun 18:e180132. [Abstract]
- J Ethnopharmacol. 2024 Jan 30;319(Pt 1):117162. [Abstract]
- Cell Mol Life Sci. 2025 Jul 3;82(1):270. [Abstract]
- Cell Mol Life Sci. 2024 Jul 6;81(1):289. [Abstract]
- Cell Biosci. 2023 Oct 3;13(1):186. [Abstract]
- Commun Biol. 2026 May 14. [Abstract]
- Eur J Pharmacol. 2025 Sep 15:1003:177890. [Abstract]
- Int Immunopharmacol. 2024 Jul 18:139:112669. [Abstract]
- Am J Respir Cell Mol Biol. 2026 Jun 23:aanag113. [Abstract]
- J Pathol. 2020 Dec;252(4):358-370. [Abstract]
- Cancers (Basel). 2023 Jun 3;15(11):3043. [Abstract]
- J Cell Mol Med. 2025 Jul;29(14):e70710. [Abstract]
- Oncol Rep. 2018 Apr;39(4):1919-1929. [Abstract]
- Mol Oncol. 2025 Jun;19(6):1668-1686. [Abstract]
- iScience. 2024 Jun 29;27(8):110424. [Abstract]
- J Virol. 2026 Apr 29:e0018226. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Jun 6:159642. [Abstract]
- Mol Carcinog. 2023 Jul;62(7):963-974. [Abstract]
- Exp Eye Res. 2026 May:266:110932. [Abstract]
- Tissue Cell. 2025 Sep 9:98:103134. [Abstract]
- Exp Eye Res. 2025 Jan 10:110239. [Abstract]
- Br J Nutr. 2024 Feb 28;131(4):553-566. [Abstract]
- Anal Cell Pathol. 2026;2026(1):e6120748. [Abstract]
- Oncol Lett. 2020 Sep;20(3):2855-2869. [Abstract]
- Biol Pharm Bull. 2022 Apr 1;45(4):438-445. [Abstract]
- Res Sq. 2026 Jun 15.
- University of Tubingen. 2025.
- Res Sq. 2024 Nov 18.
- Research Square Preprint. 2022 May.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
2D/3D Cell Culture and Differentiation
-
WB
-
WB
-
Cell Proliferation/Viability Assay
Activité biologique
Fatostatin hydrobromide (125B11 hydrobromide) (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin hydrobromide inhibits insulin-induced adipogenesis of 3T3-L1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU-145 cells
-
Concentration:0.1, 1 μM
-
Incubation Time:3 days
-
Result:Impaired the IGF1-induced growth at an IC50 of 0.1 μM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Four-to-five-week-old homozygous male obese (ob/ob) mice (C57BL/6J)[2]
-
Dosage:30 mg/kg; 150 mL
-
Administration:i.p. injection; daily for 28 days
-
Result:Blocked increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake.
Chemical Information
-
CAS No. 298197-04-3
-
Appearance Solid
-
Masse moléculaire 375.33
-
Formule C18H19BrN2S
-
Color Light yellow to yellow
-
SMILES
CCCC1=NC=CC(C2=NC(C3=CC=C(C)C=C3)=CS2)=C1.[H]Br
-
Synonyms
125B11 hydrobromide
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (56)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Apr;652(8108):209-219. PMID: 41781621 -
Cancer Cell
2024 Sep 26:S1535-6108(24)00350-7. PMID: 39366375
Fatostatin hydrobromide purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Sep 26:S1535-6108(24)00350-7. [Abstract]
Representative images of rat mammary organoids treated with Midkine (300 ng/mL), Betulin (5 μM), Fatostatin (5 μM) and Rapamycin (25 nM) for 5 days.
Fatostatin hydrobromide purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Sep 26:S1535-6108(24)00350-7. [Abstract]
Immunoblot showing the expression of MDK, mature SREBF1 (SREBF1 (M)), S6, p-S6(Ser235/236), AKT, p-AKT(Ser473) in the organoids treated with Midkine (300 ng/mL), Betulin (5 μM), Fatostatin (5 μM) and Rapamycin (25 nM) for 5 days. Tubulin serves as loading control.
-
Cell Metab
TMEM41B acts as an ER scramblase required for lipoprotein biogenesis and lipid homeostasis. [Abstract]2021 Aug 3;33(8):1655-1670.e8. PMID: 34015269 -
Cell Mol Immunol
YDJC restrains Th1 cell differentiation by blocking SREBP2-mediated cholesterol biosynthesis to alleviate mucosal inflammation in inflammatory bowel disease. [Abstract]2025 Oct 29. PMID: 41162693 -
Autophagy
Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway. [Abstract]2021 Jul;17(7):1592-1613. PMID: 32432943 -
Nat Commun
The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis. [Abstract]2026 Jan 20;17(1):614. PMID: 41559041 -
Nat Commun
Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation. [Abstract]2025 Feb 25;16(1):1774. PMID: 40000627
Fatostatin hydrobromide purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 25;16(1):1774. [Abstract]
Viable cell numbers and PUFA-PC ratio after treatment with LY294002 (iPI3K, 10 µM), Picropodophyllin (iRTK, 10 µM), Ipatasertib (iAkt, 10 µM), or Fatostatin (iSREBP1, 20 µM) for 48 h.
-
Nat Commun
Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism. [Abstract]2025 Feb 1;16(1):1241. PMID: 39890808 -
J Clin Invest
ICOS regulates IL-10 production in group 2 innate lymphoid cells via cholesterol and cortisol biosynthesis. [Abstract]2025 Jul 8:e193134. PMID: 40627441 -
J Exp Clin Cancer Res
The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming. [Abstract]2019 May 29;38(1):228. PMID: 31142342 -
Adv Sci (Weinh)
Malignant Hepatoblast-Like Cells Sustain Stemness via IGF2-Dependent Cholesterol Accumulation in Hepatoblastoma. [Abstract]2025 Apr 24:e2407671. PMID: 40271711 -
Cell Death Differ
2021 Jun;28(6):2001-2018. PMID: 33469231 -
Cell Death Dis
GIPC2 regulation of the PKM2/SREBP1 signaling axis controls adipogenic differentiation of mesenchymal stem cells. [Abstract]2026 Jan 7;17(1):5. PMID: 41500998 -
Cell Death Dis
MARCH8 suppresses hepatocellular carcinoma by promoting SREBP1 degradation and modulating fatty acid de novo synthesis. [Abstract]2025 May 16;16(1):391. PMID: 40379644 -
Cell Mol Biol Lett
CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation. [Abstract]2024 Aug 21;29(1):112. PMID: 39169280 -
Cell Death Dis
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. [Abstract]2024 Jun 12;15(6):411. PMID: 38866777 -
Cell Death Dis
Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma. [Abstract]2021 May 26;12(6):544. PMID: 34039951 -
Cancer Lett
2024 Jun 18:217068. PMID: 38901665 -
Cell Death Discov
The interplay of transcriptional coregulator NUPR1 with SREBP1 promotes hepatocellular carcinoma progression via upregulation of lipogenesis. [Abstract]2022 Oct 28;8(1):431. PMID: 36307402
Fatostatin hydrobromide purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2022 Oct 28;8(1):431. [Abstract]
NUPR1 overexpression‐induced lipogenic enzymes expression can be suppressed by co-incubation with Fatostatin (20 μM; 48 h) in MHCC-97H and SK-Hep1 cells.
Fatostatin hydrobromide purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2022 Oct 28;8(1):431. [Abstract]
Transwell migration assay. Fatostatin reduces the migration ability of NUPR1-overexpressing MHCC-97H cells.
-
NPJ Precis Oncol
SOCS5-RBMX stimulates SREBP1-mediated lipogenesis to promote metastasis in steatotic HCC with HBV-related cirrhosis. [Abstract]2024 Mar 1;8(1):58. PMID: 38429411 -
Mol Med
G protein-coupled estrogen receptor activates PI3K/AKT/mTOR signaling to suppress ferroptosis via SREBP1/SCD1-mediated lipogenesis. [Abstract]2024 Feb 21;30(1):28. PMID: 38383297 -
Free Radic Biol Med
FATP5 deficiency alleviates MASH via remodeling hepatic lipid composition to suppress ferroptosis. [Abstract]2025 Aug 19:240:170-182. PMID: 40840619 -
Cancer Immunol Res
2025 Dec 9. PMID: 41364085 -
Cell Rep
HSPA8 dampens SCAP/INSIG split and SREBP activation by reducing PKR-mediated INSIG phosphorylation. [Abstract]2025 Feb 19;44(3):115339. PMID: 39977267 -
Cell Rep
Tim-4 reprograms cholesterol metabolism to suppress antiviral innate immunity by disturbing the Insig1-SCAP interaction in macrophages. [Abstract]2022 Nov 29;41(9):111738. PMID: 36450259 -
Emerg Microbes Infect
SREBP2-dependent lipid droplet formation enhances viral replication and deteriorates lung injury in mice following IAV infection. [Abstract]2025 Dec;14(1):2470371. PMID: 39968754 -
J Ethnopharmacol
Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]2026 Feb 28:357:120890. PMID: 41232632 -
JCI Insight
Regulatory T-cell and neutrophil extracellular traps interaction contributes to the development of immunosuppression in sepsis. [Abstract]2024 Jun 18:e180132. PMID: 38888975 -
J Ethnopharmacol
Corydalis saxicola Bunting total alkaloids improve NAFLD by suppressing de novo lipogenesis through the AMPK-SREBP1 axis. [Abstract]2024 Jan 30;319(Pt 1):117162. PMID: 37690477 -
Cell Mol Life Sci
Aquaglyceroporin-7 ameliorates sorafenib resistance and immune evasion in hepatocellular carcinoma through inhibition of lipid accumulation. [Abstract]2025 Jul 3;82(1):270. PMID: 40610622 -
Cell Mol Life Sci
Human cytomegalovirus infection impairs neural differentiation via repressing sterol regulatory element binding protein 2-mediated cholesterol biosynthesis. [Abstract]2024 Jul 6;81(1):289. PMID: 38970696 -
Cell Biosci
Gut microbial metabolite deoxycholic acid facilitates Th17 differentiation through modulating cholesterol biosynthesis and participates in high-fat diet-associated colonic inflammation. [Abstract]2023 Oct 3;13(1):186. PMID: 37789469 -
Commun Biol
Pyruvate carboxylase promotes SREBP1a-mediated lipid synthesis in epithelial ovarian cancer. [Abstract]2026 May 14. PMID: 42129486 -
Eur J Pharmacol
Effectiveness and safety of the SREBP1/2 inhibitor, fatostatin, in a preclinical model of metabolic dysfunction-associated steatotic liver disease progression. [Abstract]2025 Sep 15:1003:177890. PMID: 40617382 -
Int Immunopharmacol
Alcohol intake exacerbates experimental autoimmune prostatitis through gut microbiota driving cholesterol biosynthesis-mediated Th17 differentiation. [Abstract]2024 Jul 18:139:112669. PMID: 39029231 -
Am J Respir Cell Mol Biol
Pathogenic Rewiring of IL6 Signaling Fuels Macrophage Immunometabolic reprogramming in COPD. [Abstract]2026 Jun 23:aanag113. PMID: 42334931 -
J Pathol
ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p. [Abstract]2020 Dec;252(4):358-370. PMID: 32770671 -
Cancers (Basel)
SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. [Abstract]2023 Jun 3;15(11):3043. PMID: 37297005 -
J Cell Mol Med
2025 Jul;29(14):e70710. PMID: 40682485 -
Oncol Rep
Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. [Abstract]2018 Apr;39(4):1919-1929. PMID: 29436682 -
Mol Oncol
Combined spatially resolved metabolomics and spatial transcriptomics reveal the mechanism of RACK1-mediated fatty acid synthesis. [Abstract]2025 Jun;19(6):1668-1686. PMID: 39425259 -
iScience
Influenza A virus infection activates STAT3 to enhance SREBP2 expression, cholesterol biosynthesis, and virus replication. [Abstract]2024 Jun 29;27(8):110424. PMID: 39108727 -
J Virol
Pvf/Pvr signaling relieves white spot syndrome virus-induced lipid consumption to inhibit viral infection in shrimp. [Abstract]2026 Apr 29:e0018226. PMID: 42053404 -
Biochim Biophys Acta Mol Cell Biol Lipids
Tumor necrosis factor alpha-induced activation of SREBP2 promotes cholesterol biosynthesis in cholestasis. [Abstract]2025 Jun 6:159642. PMID: 40484275 -
Mol Carcinog
LATS-regulated nuclear-cytoplasmic translocation of SREBP2 inhibits hepatocellular carcinoma cell migration and invasion via epithelial-mesenchymal transition. [Abstract]2023 Jul;62(7):963-974. PMID: 37042569 -
Exp Eye Res
SREBP1-driven SCD1 protects retinal pigment epithelium from oxidative damage by activating the NRF2/GPX4 axis. [Abstract]2026 May:266:110932. PMID: 41720386 -
Tissue Cell
Intracellullar cholesterol accumulation caused by HBV induces ATF6-mediated endoplasmic reticulum stress to trigger endoplasmic reticulophagy. [Abstract]2025 Sep 9:98:103134. PMID: 40934546 -
Exp Eye Res
SREBF1 facilitates pathological retinal neovascularization by reprogramming the fatty acid metabolism of endothelial cells. [Abstract]2025 Jan 10:110239. PMID: 39800283 -
Br J Nutr
Dietary palm oil enhances SREBP2-mediated cholesterol biosynthesis through inducing endoplasmic reticulum stress in muscle of large yellow croaker ( Larimichthys crocea). [Abstract]2024 Feb 28;131(4):553-566. PMID: 37699661 -
Anal Cell Pathol
Identification of the Antioxidant Enzyme B166 as a Novel Biomarker for Patients With Glioblastoma Multiforme. [Abstract]2026;2026(1):e6120748. PMID: 41810932 -
Oncol Lett
SREBP1 silencing inhibits the proliferation and motility of human esophageal squamous carcinoma cells via the Wnt/β-catenin signaling pathway. [Abstract]2020 Sep;20(3):2855-2869. PMID: 32765792 -
Biol Pharm Bull
Inhibition of Stearoyl-CoA Desaturase 1 Potentiates Anti-tumor Activity of Amodiaquine in Non-small Cell Lung Cancer. [Abstract]2022 Apr 1;45(4):438-445. PMID: 35110426 -
-
-
-
Solvant et solubilité
DMSO : 25 mg/mL (66.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1 mg/mL (2.66 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Choi Y, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J Biol Chem. 2003 Feb 28;278(9):7320-4. [Content Brief]
[2]. Kamisuki S, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol. 2009 Aug 28;16(8):882-92. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6643 mL | 13.3216 mL | 26.6432 mL | 66.6081 mL |
| 5 mM | 0.5329 mL | 2.6643 mL | 5.3286 mL | 13.3216 mL | |
| 10 mM | 0.2664 mL | 1.3322 mL | 2.6643 mL | 6.6608 mL | |
| 15 mM | 0.1776 mL | 0.8881 mL | 1.7762 mL | 4.4405 mL | |
| 20 mM | 0.1332 mL | 0.6661 mL | 1.3322 mL | 3.3304 mL | |
| 25 mM | 0.1066 mL | 0.5329 mL | 1.0657 mL | 2.6643 mL | |
| 30 mM | 0.0888 mL | 0.4441 mL | 0.8881 mL | 2.2203 mL | |
| 40 mM | 0.0666 mL | 0.3330 mL | 0.6661 mL | 1.6652 mL | |
| 50 mM | 0.0533 mL | 0.2664 mL | 0.5329 mL | 1.3322 mL | |
| 60 mM | 0.0444 mL | 0.2220 mL | 0.4441 mL | 1.1101 mL |
Fatostatin hydrobromide Related Classifications
HY-14452A Related Classifications
Powered by Bioz